Publications
  1. LONGITUDINAL EFFECTS OF 12 MONTHS SMOKING CESSATION ON DNA METHYLATION AND GENE EXPRESSION IN BRONCHIAL BIOPSIES

    Rathnayake, S., Vermeulen, C., Hacken, T. N., Timens, W., Kooistra, W., Heijink, H., Brandsma, C., Oliver, B., Van Den Berge, M. & Faiz, A., Jun-2020, In : Respirology. 25, p. 30-30 1 p.

    Research output: Contribution to journalMeeting AbstractAcademic

  2. Interobserver variation in the classification of thymic lesions including biopsies and resection specimens in an international digital microscopy panel

    Wolf, J. L., van Nederveen, F., Blaauwgeers, H., Marx, A., Nicholson, A. G., Roden, A. C., Ströbel, P., Timens, W., Weissferdt, A., von der Thüsen, J. & den Bakker, M. A., 7-Jun-2020, In : Histopathology.

    Research output: Contribution to journalArticleAcademicpeer-review

  3. The Genetic Epidemiology of Pediatric Pulmonary Arterial Hypertension

    Haarman, M. G., Kerstjens-Frederikse, W. S., Vissia-Kazemier, T. R., Breeman, K. T. N., Timens, W., Vos, Y. J., Roofthooft, M. T. R., Hillege, H. L. & Berger, R. M. F., 2-Jun-2020, In : The Journal of Pediatrics. 44 p.

    Research output: Contribution to journalArticleAcademicpeer-review

View all (489) »

Activities
  1. MicroRNAs as regulators of lung homeostasis, abnormal repair and ageing.

    Joost Kluiver (Co-supervisor), Anke Berg, van den (Supervisor), Wim Timens (Supervisor), Corry-Anke Brandsma (Supervisor)
    2019

    Activity: ExaminationSupervision of PhD studentsAcademic

  2. Nederlandse Vereniging voor Pathologie (NVVP) (External organisation)

    Wim Timens (Chair)
    1-Jul-20191-Sep-2021

    Activity: MembershipMembership of committeeProfessional

  3. EMEAC Regional Advisory Board Europe

    Wim Timens (Consultant)
    6-Nov-2019

    Activity: ConsultancyProfessional

View all (55) »

Press / Media
  1. Kankercellen onder de loep

    Wim Timens & Bert van der Vegt

    16/04/2019

    1 item of Media coverage

    Press/Media: Public Engagement ActivitiesPopular

  2. Zien welke kanker het is

    Bert Vegt, van der & Willem Timens

    13/04/2019

    1 item of Media coverage

    Press/Media: Public Engagement ActivitiesPopular

  3. PD-L1 kleuring vereist bij eerstelijnsbehandeling urotheelcarcinoom met pembrolizumab

    Wim Timens

    01/04/2019

    1 item of Media coverage

    Press/Media: Expert CommentProfessional

View all (5) »

ID: 152285